Overview

A Study of Abicipar Pegol in Patients With Neovascular Age-related Macular Degeneration

Status:
Completed
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
This is a safety and efficacy study of abicipar pegol in patients with neovascular age-related macular degeneration to establish comparability between Japanese and non-Japanese.
Phase:
Phase 2
Details
Lead Sponsor:
Allergan
Treatments:
Ranibizumab